A US-based KOL provides insights into epidemiology, prescribing habits, key marketed brands and late-phase pipeline therapies for colorectal cancer. Treatment strategies and unmet needs are also discussed. Key pipeline assets highlighted include GRANITE, PolyPEPI1018, zanzalintinib and favezelimab. 

This interview was conducted on Nov. 12, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.